EMAIL THIS PAGE TO A FRIEND

Drug research

Influence of beta-cyclodextrin and chitosan in the formulation of a colon-specific drug delivery system.


PMID 23842943

Abstract

The increase in diseases of the colon underscores the need to develop cost-effective site-directed therapies. We formulated a polysaccharide-based matrix system that could release ibuprofen under conditions simulating those in the colon by employing a wet granulation method. Tablets were prepared in a series of formulations containing a polysaccharide (beta-cyclodextrin and chitosan) matrix system along with ethylcellulose. We characterized physicochemical properties and performed an in vitro drug release assay in the absence and presence of digestive enzymes to assess the ability of the polysaccharides to function as a protective barrier against the upper gastrointestinal environment. Fourier transform infrared spectroscopy studies revealed no chemical interaction between ibuprofen and polysaccharides; however, spectrum analysis suggested the formation of an inclusion complex of beta-cyclodextrin with ibuprofen. The formulations contained 50% ethylcellulose and 50% beta-cyclodextrins (1:1) were proven to be the better formulation that slowly released the drug until 24 h (101.04 ± 0.65% maximum drug release in which 83.08 ± 0.89% drug was released in colonic medium) showed better drug release profiles than the formulations containing chitosan. We conclude that a beta-cyclodextrin drug carrier system may represent an effective approach for treatment of diseases of the colon.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

375160
(S)-(+)-Ibuprofen, ReagentPlus®, 99%
C13H18O2
C4767
β-Cyclodextrin, ≥97%
C42H70O35
C4805
β-Cyclodextrin, powder, BioReagent, suitable for cell culture, ≥97%
C42H70O35
W402826
β-Cyclodextrin, produced by Wacker Chemie AG, Burghausen, Germany
C42H70O35
779105
β-Cyclodextrin, produced by Wacker Chemie AG, Burghausen, Germany, ≥95.0% (HPLC)
C42H70O35
779334
β-Cyclodextrin, Produced by Wacker Chemie AG, Burghausen, Germany, Life Science, ≥98.0% (HPLC)
C42H70O35
200646
Ethyl cellulose, viscosity 4 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
200689
Ethyl cellulose, viscosity 10 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
200697
Ethyl cellulose, viscosity 22 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
433837
Ethyl cellulose, viscosity 46 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
247499
Ethyl cellulose, viscosity 100 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
200654
Ethyl cellulose, viscosity 300 cP, 5 % in toluene/ethanol 80:20(lit.), extent of labeling: 48% ethoxyl
46070
Ethyl cellulose, 48.0-49.5% (w/w) ethoxyl basis
46080
Ethyl cellulose, 48.0-49.5% (w/w) ethoxyl basis
I1892
Ibuprofen sodium salt, analytical standard, ≥98% (GC)
C13H17NaO2
I-009
Ibuprofen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C13H17O2